Kinetic characterization of amyloid-beta 1-42 aggregation with a multimethodological approach.
暂无分享,去创建一个
Fabio Biscarini | Marina Naldi | Vincenza Andrisano | Francesco Valle | V. Andrisano | M. Bartolini | M. Naldi | J. Fiori | D. Nicolau | F. Biscarini | Manuela Bartolini | Dan V Nicolau | F. Valle | Jessica Fiori
[1] D. Kirschner,et al. Alzheimer's beta-amyloid: insights into fibril formation and structure from Congo red binding. , 2005, Sub-cellular biochemistry.
[2] Dong Jin Kim,et al. Bis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for Abeta fibril formation. , 2007, Bioorganic & medicinal chemistry letters.
[3] D. Selkoe. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. , 2001, Journal of Alzheimer's disease : JAD.
[4] E. Bergantino,et al. Conformational Equilibria in Monomeric α-Synuclein at the Single-Molecule Level , 2008, PLoS biology.
[5] D. Butterfield,et al. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. , 2000, Journal of structural biology.
[6] D. Pastré,et al. Mica surface promotes the assembly of cytoskeletal proteins. , 2009, Langmuir : the ACS journal of surfaces and colloids.
[7] A. Takashima,et al. Potent anti‐amyloidogenic and fibril‐destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease , 2003, Journal of neurochemistry.
[8] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[9] T. Morgan,et al. Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies , 2001, Journal of neurochemistry.
[10] S. Shimohama,et al. Effects of nicotinic receptor agonists on beta-amyloid beta-sheet formation. , 1999, Japanese journal of pharmacology.
[11] J. Cladera,et al. Conversion of non-fibrillar beta-sheet oligomers into amyloid fibrils in Alzheimer's disease amyloid peptide aggregation. , 2007, Biochemical and biophysical research communications.
[12] D. Selkoe,et al. Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.
[13] T. Kihara,et al. Multifunction of myricetin on Aβ: Neuroprotection via a conformational change of Aβ and reduction of Aβ via the interference of secretases , 2008 .
[14] K. Davis,et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.
[15] M. Hosokawa,et al. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. , 1989, Analytical biochemistry.
[16] R. Kayed,et al. Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.
[17] D. Middleton. Solid-state NMR spectroscopy as a tool for drug design: from membrane-embedded targets to amyloid fibrils. , 2007, Biochemical Society transactions.
[18] Min Zhu,et al. Annular Oligomeric Amyloid Intermediates Observed by in Situ Atomic Force Microscopy* , 2004, Journal of Biological Chemistry.
[19] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[20] D. Selkoe,et al. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. , 2004, Protein and peptide letters.
[21] D. Selkoe,et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. , 1999, The Journal of biological chemistry.
[22] V. Andrisano,et al. Strategies for the Inhibition of Protein Aggregation in Human Diseases , 2010, Chembiochem : a European journal of chemical biology.
[23] D. Selkoe,et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.
[24] Peter T. Lansbury,et al. Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease† , 1999 .
[25] D. Teplow,et al. Amyloid β-Protein Assembly and Alzheimer Disease* , 2009, Journal of Biological Chemistry.
[26] S. Müller,et al. Multiple Assembly Pathways Underlie Amyloid-β Fibril Polymorphisms , 2005 .
[27] Nigel J Fullwood,et al. Both the D-(+) and L-(-) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity. , 2004, Biochemistry.
[28] D. Teplow,et al. Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences. , 2008, Journal of molecular biology.
[29] Alexander J. Rivest,et al. Characterization of β amyloid assemblies in drusen: The deposits associated with aging and age-related macular degeneration , 2004 .
[30] P. Lansbury,et al. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. , 1997, Chemistry & biology.
[31] G. Bitan,et al. Neurotoxic protein oligomers — what you see is not always what you get , 2005, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[32] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[33] W. Klein,et al. Conformation‐dependent single‐chain variable fragment antibodies specifically recognize beta‐amyloid oligomers , 2009, FEBS letters.
[34] Hai Lin,et al. Imaging real-time aggregation of amyloid beta protein (1–42) by atomic force microscopy , 2002, Peptides.
[35] M. Przybylski,et al. Interaction of beta-amyloid(1-40) peptide with pairs of metal ions: An electrospray ion trap mass spectrometric model study. , 2009, Biophysical chemistry.
[36] M. Kirkitadze,et al. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[37] W. B. Stine,et al. The nanometer-scale structure of amyloid-Β visualized by atomic force microscopy , 1996 .
[38] A. Murase,et al. Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. , 2009, The American journal of pathology.
[39] I. Mook‐Jung,et al. Aminostyrylbenzofuran derivatives as potent inhibitors for Abeta fibril formation. , 2008, Bioorganic & medicinal chemistry letters.
[40] M. Findeis. The role of amyloid β peptide 42 in Alzheimer's disease , 2007 .
[41] E. Giralt,et al. Fine structure study of Aβ1–42 fibrillogenesis with atomic force microscopy , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[42] T. Iwatsubo,et al. Small Molecule Inhibitors of α-Synuclein Filament Assembly† , 2006 .
[43] A. Cavalli,et al. Insight Into the Kinetic of Amyloid β (1–42) Peptide Self‐Aggregation: Elucidation of Inhibitors’ Mechanism of Action , 2007, Chembiochem : a European journal of chemical biology.
[44] R. Kayed,et al. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis , 2006, Neurology.
[45] C. Bustamante,et al. Substrate preparation for reliable imaging of DNA molecules with the scanning force microscope. , 1992, Ultramicroscopy.
[46] R. Riek,et al. 3D structure of Alzheimer's amyloid-β(1–42) fibrils , 2005 .
[47] F. Gejyo,et al. Kinetic analysis of amyloid fibril formation. , 1999, Methods in enzymology.
[48] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[49] B Urbanc,et al. Elucidation of amyloid beta-protein oligomerization mechanisms: discrete molecular dynamics study. , 2010, Journal of the American Chemical Society.
[50] E. Bergantino,et al. The reaction of alpha-synuclein with tyrosinase: possible implications for Parkinson disease. , 2008, The Journal of biological chemistry.
[51] D. Walsh,et al. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.
[52] G. Bitan,et al. Amyloid β-protein: Monomer structure and early aggregation states of Aβ42 and its Pro19 alloform , 2005 .
[53] M. Fändrich,et al. The aggregation kinetics of Alzheimer's β‐amyloid peptide is controlled by stochastic nucleation , 2005, Protein science : a publication of the Protein Society.
[54] P. Hough,et al. High-resolution Atomic Force Microscopy of Soluble Aβ42 Oligomers , 2006 .
[55] G. Bitan. Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. , 2006, Methods in enzymology.
[56] Peter T. Lansbury,et al. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy , 1997 .
[57] L. Olsen,et al. Study on the binding of Thioflavin T to β-sheet-rich and non- β-sheet cavities , 2007 .
[58] W. Klein,et al. Salvianolic acid B inhibits Aβ fibril formation and disaggregates preformed fibrils and protects against Aβ-induced cytotoxicty , 2008, Neurochemistry International.
[59] T. Zako,et al. Amyloid oligomers: formation and toxicity of Aβ oligomers , 2010, The FEBS journal.